Member Info for Brighty1

Yes, QBT hasn't even started it's mega gain yet. BANK today up 2,000% in the month from 0.5 to 10p (make that 11p now!!) ....

Good luck, Brighty

Exactly, this looks much bigger than first thought. Silver is priced today at £25.01 per ounce....

Good luck, Brighty

Exactly Steve and Massive. This has all the makings of at least a billion pound business. It's a hold for gold x 100 opportunity. Right share. Right time.....

Good luck, Brighty

This doesn't look like "waffle" anymore!...

* Following almost three years of R&D efforts, the AI team working on Method C has delivered its first irrefutable result, with a new version of Method C AI Oracle, which can now be used to mine the current blockchain blocks in real-time with an approximate 30% improved performance. This has been made possible thanks to retraining the Method C model and to a very efficient hardware implementation of the AI Oracle, which forms the core of the “Implementation of Binary Decision Trees” patent application.

* This has the potential to be a major breakthrough for the entire Bitcoin mining industry, as QBT has developed an AI Oracle which can either reduce the energy cost of mining or increase the speed of mining at current energy costs, by approximately 30%, which it can prove through live demonstrations.

* Following the filing of its new patent application the Company is now in a position to demonstrate its FPGA-based live Bitcoin mining, via a mining pool, to potential clients who it anticipates primarily will be hardware manufacturers.

* The board of directors currently believes that working in commercial partnership with a major hardware manufacturer via a licensing agreement, will be the most logical route to market, principally due to the cost benefits to QBT when transferring its disruptive technology from an FPGA to the most competitive ASIC in the market

Maybe, just maybe, QBT is on to something with Model C? I had been sitting on the sidelines until recently when I bought in to QBT a few weeks ago just in case! It's going to be interesting because if they can leverage a "licencing deal" as they propose today in the RNS this could go stratospheric.....

Good luck, Brighty

Exactly, Comek. The Semnet and CAKE deals are transformational for GST. The value of both are not even priced in yet. Plus,if they do acquire Easysend then it just gets better and better from a growth trajectory and value inflection perspective. 2025 is going to be big for GST and its shareholders....

Good luck, Brighty

Exactly, AVCT must be a takeover target in the industry now as today there is yet more proof of the transformative potential of AVCT's preCISION programme for treating not just SGC but more importantly other solid tumors too. This is very encouraging and most importantly commercially significant for a takeover or on-licencing deal.....

Good luck, Brighty

Exactly, The City are going to absolutely love the GST numbers in due course. CAKE adds a definitive revenue stream to the GST business that is going to make everyone in the City take notice of GST this year. The number crunchers on here will know that CAKE's EBIT was $30 million US dollars in 2022 and had been as high as $206 million US dollars in 2021. Those are astounding results for a relatively new and small company. Don't forget that even if those revenues have depleted at CAKE to say just 10% of the 2021/22 numbers the positive impact on GST's figures will still be very significant indeed. In summary, I expect to see £1+ a share over the next few years not a few pence....

Good luck, Brighty

Exactly and the Stephen Wolstenhulme I'm aware of is the wealth manager at Redmayne Bentley. That's a big vote of confidence in VAL if it's him.....

Good luck, Brighty

On 14 November'23 GST announced a placing. 15 days later the Easysend deal was announced and 8 days later the Semnet deal was announced. It is therefore likely that an acquisition is in the pipeline. Maybe it's the final consideration payment to secure a deal for Easysend? We might hear soon.....

Good luck, Brighty

Exactly right Laura, Kinghomer, Basil, JungleVP and Co. TRLS up 630%+ already today is a great example of what can happen with these small bio stocks. We know it can happen here too: 1p to 30p+ in 2017 & 1p to 10p in 2020.....

Good luck, Brighty

Exactly, GST would be acquiring a ready made customer base with Easysend:

* €120 million transaction volume in 23/24

* Approx 40,000 individual customers in 23/24

* Approx 350 active corporate customers in 23/24

Normally, after a raise at GST a deal is announced / confirmed soon afterwards. Watch this space....

Good luck, Brighty

Having read the recent RNS' I would say that the raise could be to complete on EasySend. That would be a brilliant outcome ...

Good luck, Brighty

Exactly and what you need to focus on is that GST has acquired a revenue making business with CAKE. EBIT was 30 million USD in 2022 and had been as high as 206 million USD in 2021. Even if the revenues are significantly less the GST figures will increase dramatically. The City / investors are going to love the numbers here soon. I'm invested for the journey to £1 a share over the next few years not a few pence....

Good luck, Brighty

Exactly, I don't disagree with you but JR and SP were certainly inferring (in my opinion) during the Investor Meeting that there was both a commercial and scientific reason behind the additional longer term Pre-P2 toxicology studies that they are now working on. I believe that they are aiming to conclusively prove to big pharma that SDC1801 is the real deal. That's the value inflection point for everyone. Based on the fact that they have achieved a x 30 for me in the past I am inclined to give them the benefit of the doubt that they have been asked to do additional research by a major pharma or big investor. It's in the public domain already that both single ascending dose and multiple ascending dose stages were successful, so a peer review is all about adding credibility infront of the R&D Directors at big pharma. This could also create a bidding war. i.e. You never want to go in to negotiations with just one bidder. In summary, the peer review will help create awareness and that's commercially a good thing....

Good luck, Brighty

Yes, Aberystwyth it would be great to wake up to an RNS like that GSK IDRx acquisition for 1 Billion+ today. I have been expecting a bounce in our share price for quite a while. To achieve a change in the share price direction/decline we need the SDC1801 peer review published soon. Once that occurs interest from a big pharma might be forthcoming. However, I agree we need more urgency to be shown from the BOD. 2025 heralds 21 years in business for SAR....

Good luck, Brighty

Exactly, Revolut must be looking at Crypto as a bolt on. The CAKE transaction has certainly catapulted GST into another league and won't have gone un-noticed by the BOD's at Revolut and the traditional players such as HSBC & Standard Chartered, all of whom have a significant Singapore presence. It does beg the question just how much is GST going to be worth by the end of 2025 and then moving forwards? Revolut's market cap is currently $45 billion....

Good luck, Brighty

One day we will wake up to an announcement like this. i.e. Yet another £1 Billion takeover announced today (13th January 2025) in our sector with GSK buying IDRx for 1 Billion upfront and 150 Million in extras. Come on Stephen Parker and John Reader get on with it please......

Details below:

· Acquisition includes IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST)

· IDRX-42 offers potential to address all key KIT mutations in GIST that drive tumour growth and progression and improve tolerability, gaps in current therapies

· Acquisition adds to GSK's growing portfolio in gastrointestinal (GI) cancers

· GSK to pay up to $1.15 billion

Good luck, Brighty

Exactly and what you need to focus on is that GST has acquired a revenue making business with CAKE.

The gross revenue in 2022 was 228 million USD and had been 619 million USD in 2021. Net revenue was 64 million USD and had been 222 million USD in 2021. EBIT was 30 million USD in 2022 and had been as high as 206 million USD in 2021. Even if the revenues are significantly less the GST figures will increase dramatically. The City / investors are going to love the numbers here soon…..

Good lucky, Brighty

Exactly, Astellas Pharma Market Cap was 17.32B yesterday. Peer-reviewed articles endorse small bio's infront of the R&D directors of the major players so this is not to be sniffed at.

i.e. It showcases PYC working with a 17.3 Billion MCAP global pharma, it highlights the high-quality consultancy services and working relationship provided to Astellas and it promotes PYC's Virtual Tumour Platform. Win win....

Good luck, Brighty

Exactly BoilB. It states "Approved on Aria"....

Good luck, Brighty